| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044480489 |
| P356 | DOI | 10.1038/SJ.CGT.7700851 |
| P698 | PubMed publication ID | 15891772 |
| P5875 | ResearchGate publication ID | 7849117 |
| P50 | author | Luisa Barzon | Q60011989 |
| Giorgio Palù | Q67154939 | ||
| Monia Pacenti | Q114452192 | ||
| Elisa Franchin | Q114452193 | ||
| P2093 | author name string | Federico Colombo | |
| Daniela Danieli | |||
| Vittore Pinna | |||
| Mariano Zanusso | |||
| P2860 | cites work | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| The prothrombotic state in cancer: pathogenic mechanisms | Q34325216 | ||
| Influence of the bystander effect on HSV-tk/GCV gene therapy. A review | Q34791457 | ||
| American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells | Q35195407 | ||
| Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors | Q35228764 | ||
| Endocrine aspects of cancer gene therapy | Q35652687 | ||
| High-titer packaging cells producing recombinant retroviruses resistant to human serum | Q35851698 | ||
| Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses | Q40611932 | ||
| Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir | Q41576545 | ||
| Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase | Q42806173 | ||
| Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer | Q42824650 | ||
| Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. | Q43636591 | ||
| Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans | Q43689849 | ||
| Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient. | Q43945636 | ||
| Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer | Q44204081 | ||
| Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy | Q44742482 | ||
| Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
| AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study | Q45127753 | ||
| A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. | Q45739549 | ||
| A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group | Q45862712 | ||
| Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results | Q45863348 | ||
| Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells | Q45887851 | ||
| Gene stereotactic neurosurgery for recurrent malignant gliomas | Q45888902 | ||
| Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells | Q48587406 | ||
| Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study | Q48590023 | ||
| Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. | Q54635100 | ||
| Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line | Q55245697 | ||
| A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma | Q58659735 | ||
| P433 | issue | 10 | |
| P921 | main subject | patient | Q181600 |
| gene therapy | Q213901 | ||
| glioblastoma | Q282142 | ||
| P304 | page(s) | 835-848 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Cancer Gene Therapy | Q15763088 |
| P1476 | title | Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results | |
| P478 | volume | 12 |
| Q43888627 | Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses |
| Q92797426 | Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo |
| Q34576976 | Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity |
| Q42356992 | Bovine herpesvirus 4 based vector as a potential oncolytic-virus for treatment of glioma |
| Q37640613 | Challenges in clinical design of immunotherapy trials for malignant glioma |
| Q37970682 | Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment |
| Q36367428 | Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas |
| Q36495546 | Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems. |
| Q36325239 | Current immunotherapeutic strategies for central nervous system tumors |
| Q50109459 | Current state and future prospects of immunotherapy for glioma |
| Q38401892 | Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor |
| Q37886819 | Cytokine networks in glioma |
| Q40875816 | Dendritic cell immunotherapy for brain tumors. |
| Q41515320 | Efficacy of local delivery of ardipusilloside I using biodegradable implants against cerebral tumor growth |
| Q40208813 | Exogenous wt-p53 enhances the antitumor effect of HSV-TK/GCV on C6 glioma cells |
| Q35186312 | Gene Therapies for Cancer: Strategies, Challenges and Successes |
| Q34980337 | Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside |
| Q35673628 | Gene therapy for malignant glioma |
| Q35880459 | Gene therapy trials for the treatment of high-grade gliomas |
| Q36345439 | Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model |
| Q37580510 | Glioma virus therapies between bench and bedside |
| Q45871562 | HIV vector-mediated targeted suicide gene therapy for adult T-cell leukemia |
| Q54977772 | HSV‑TK/GCV can induce cytotoxicity of retinoblastoma cells through autophagy inhibition by activating MAPK/ERK. |
| Q35760658 | Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models |
| Q33656811 | History and current state of immunotherapy in glioma and brain metastasis |
| Q31125309 | Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis |
| Q45863017 | Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma |
| Q38870994 | Immunological Aspects of Malignant Gliomas |
| Q38912826 | Improving the safety of T-Cell therapies using an inducible caspase-9 gene |
| Q35784529 | Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation |
| Q38824797 | Interleukin-15-transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model |
| Q64057516 | Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma |
| Q33950709 | Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors |
| Q37422676 | Methods to monitor gene therapy with molecular imaging. |
| Q37079854 | Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q26776345 | Overview of current immunotherapeutic strategies for glioma |
| Q36086507 | PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma |
| Q34208293 | Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma |
| Q55457286 | Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma? |
| Q37239071 | Recent advances and future of immunotherapy for glioblastoma |
| Q36627242 | Recent clinical progress in virus-based therapies for cancer. |
| Q37818222 | Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma |
| Q37771247 | Targeted therapy in the treatment of malignant gliomas |
| Q35234447 | Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. |
| Q30689378 | The engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer |
| Q24651009 | The status of gene therapy for brain tumors |
| Q45865848 | Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus |
| Q27021951 | Trial Watch:: Oncolytic viruses for cancer therapy |
| Q37028023 | Trial watch: Oncolytic viruses for cancer therapy |
| Q50590539 | Tumor-infiltrating lymphocytes (TILs) from patients with glioma. |
| Q39922260 | Tumor-specific activity of cellular regulatory elements is down-regulated upon insertion into the herpes simplex virus genome |
| Q38243975 | Vaccine therapies for patients with glioblastoma |
Search more.